



201 Technology Drive • Irvine • California • 92618
Telephone: (949) 450-5400
Facsimile: (949) 450-5300
Email: IR@endocare.com
Website: www.endocare.com

FOR RELEASE on October 15, 2008 at 6:00 AM (EDT)

Investor Contact:

Matt Clawson
Allen & Caron, Inc.
(949) 474-4300
matt@allencaron.com
www.allencaron.com

Media Contact:

Len Hall
Allen & Caron, Inc.
(949) 474-4300
len@allencaron.com
www.allencaron.com

For Additional Information:

Terrence A. Noonan, Interim CEO
Michael R. Rodriguez, CFO
Endocare, Inc.
(949) 450-5400
www.endocare.com

**ENDOCARE AND FORMER CEO PAUL W. MIKUS AGREE
TO TERMINATE INDEMNIFICATION AGREEMENT**

IRVINE, Calif. (October 15, 2008) . . . Endocare, Inc. (NASDAQ:ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that it has entered into an agreement with its former CEO Paul W. Mikus that terminates Mr. Mikus' indemnification agreement in exchange for Endocare's waiver of certain severance and legal fee reimbursement rights. As a result of this new agreement, Endocare is no longer obligated to pay any future legal costs for Mr. Mikus.

Endocare CFO Michael R. Rodriguez said, "This agreement brings to a close our indemnification of former management and a long, expensive chapter for Endocare. It finally and immediately ends what has been a significant expense and allows management to focus more completely on building our business."

Endocare had previously announced a similar agreement with its former CFO. For more information regarding the agreement with Mr. Mikus, please see the related Form 8-K filed by Endocare today with the Securities and Exchange Commission.

About Endocare

Endocare, Inc.—www.endocare.com— is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

###